Antigenics's Oncophage Vaccine Starts Phase II Brain Tumor Trial
Posted on: Thursday, 11 October 2007, 15:00 CDT
Biotechnology company Antigenics has reported that the brain tumor research center at the University of California, San Francisco, has initiated a Phase II trial for cancer vaccine Oncophage in the treatment of recurrent glioma.
The primary objective is to evaluate overall survival in glioma patients receiving the vaccination. The trial is designed to enroll approximately 30 patients with recurrent high-grade glioma.
Patients will undergo surgery to remove their tumors, which are then used to manufacture their patient-specific vaccines. Eligible patients will be treated after surgery with oncophage once weekly for four weeks, followed by biweekly injections until vaccine depletion.
Andrew Parsa, assistant professor in the department of neurological surgery at the University of California, San Francisco, and principal investigator of the trial, said: "We are highly encouraged by the preliminary Phase I results in which we observed prolonged overall survival when compared with historical controls, as well as a tumor-specific immune response in all treated patients. Commencement of this Phase II trial with Oncophage (vitespen) is an important milestone in the advancement of this novel therapy and represents a potentially important next step in the treatment of this devastating disease."
Source: Datamonitor
Related Articles
- Altus Pharmaceuticals Reports Last Patient Visit Of Trizytek(TM) Phase 3 Efficacy Trial
- Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
- First Patient Registered in Investigator-Sponsored Phase 2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma
- Rivaroxaban Shows Superiority Over Enoxaparin in Phase III Trial Results for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
- Phase III Trial Results Show Superiority of Rivaroxaban Over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
- Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients With DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
- Nuvelo Announces Completion of Patient Enrollment in SONOMA-2, First Phase 3 Trial of Alfimeprase in Central Venous Catheter Occlusion
- Oncolytics Biotech Inc. Announces Conclusion of Patient Follow Up in Canadian Phase I Recurrent Malignant Glioma Clinical Trial
- First Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma
- Bronchial Colonization and Postoperative Respiratory Infections in Patients Undergoing Lung Cancer Surgery*
 |
 |
User Comments (0)
RSS Feeds